•  

Posts Tagged: investment

UTEST program announces investments in five U of T start-ups

Companies in fourth cohort developing products ranging from software to therapeutic platforms; applications for fifth cohort, in partnership with MLA48, open until May 27, 2016 TORONTO (May 9, 2016) — The University of Toronto Early-Stage Technology (UTEST) incubator, co-directed by U of T’s Innovations & Partnerships Office (IPO) and MaRS Innovation with financial support from the Connaught Fund, has announced five investments in start-up companies from Cohort 4. The five companies and the diverse sectors they target are: Ardra Bio, which is ... Read more

XENiOS® invests $2.6 million in XOR-Labs Toronto

Partnership expected to revolutionize the supply of transplantable lungs, with market launch in Europe by XENiOS® expected in 2017 HEILBRONN, Germany and TORONTO, Canada — XENiOS®, a commercial-stage medical device company, announced today it has invested $2.6 million in XOR-Labs Toronto (“XOR”), a spin-off of Toronto General Hospital at University Health Network (UHN), the world’s leading center for lung transplantation, created in partnership with MaRS Innovation. This announcement was covered in FierceMedicalDevices and Cystic Fibrosis News Today. VICE featured XOR's life-saving lung transplant technology ... Read more

Dr. Rafi Hofstein in Biotechnology Focus: What will it take to regain Canada’s biotechnology leadership?

Biotechnology Focus, a compendium of the Canadian life sciences industry, has published a guest column by MaRS Innovation President & CEO, Dr. Raphael Hofstein. The article explores the role life sciences assets, financing and talented management--the three Ms--must play in revitalizing Canada's biotechnology sector: At the close of the 20th century, Canada was perceived as a key contributor to the success of the global biotech voyage. You know what happened next: the mechanisms to fund early ventures collapsed together with the collapse of the ... Read more

Encycle Therapeutics Launches Ground-Breaking Chemistry Platform

Platform for cyclizing peptides promises to increase efficiency of early-stage drug discovery BOSTON, June 18, 2012 - Encycle Therapeutics, a MaRS Innovation spin-off company, has created a ground-breaking chemistry platform for cyclizing peptides that promises to increase the efficiency of the early-stage drug discovery process. Peptides have long been sought after as therapeutics due to their high specificity — they can hit specific cellular targets, especially complex protein-protein interaction targets implicated in cancer, cardiovascular disease and metabolic disorders. (more…) Read more